Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

Affiliations

Review

F H Schröder. BJU Int. 1999 Jan.

. 1999 Jan;83(2):161-70.

doi: 10.1046/j.1464-410x.1999.00955.x.

¹ Department of Urology, Erasmus University and Academic Hospital Rotterdam, The Netherlands.

No abstract available

Cited by

Prostate cancer.
Mazhar D, Waxman J. Mazhar D, et al. Postgrad Med J. 2002 Oct;78(924):590-5. doi: 10.1136/pmj.78.924.590. Postgrad Med J. 2002. PMID: 12415080 Free PMC article. Review.
The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy.
Fryczkowski M, Bryniarski P, Szczębara M, Suchodolski M, Paradysz A. Fryczkowski M, et al. Cent European J Urol. 2011;64(4):218-22. doi: 10.5173/ceju.2011.04.art6. Epub 2011 Dec 9. Cent European J Urol. 2011. PMID: 24578897 Free PMC article.
Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Shahinian VB, et al. Arch Intern Med. 2006 Feb 27;166(4):465-71. doi: 10.1001/archinte.166.4.465. Arch Intern Med. 2006. PMID: 16505268 Free PMC article.